Kuldeepak Sharma, PhD
President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
Member of the Healthcare Council
Council Member Biography
Kuldeepak Sharma, PhD, is a pharmaceutical consultant with twenty years of experience in research, clinical trials, business, patent and product development including: new process & technology development; clinical, project leadership; project planning; project management; patent research; managing research, design and engineering (R,D&E) groups. Dr. Sharma is organized, innovative and entrepreneurial. He is the inventor of ten US patents (four filed, six issued) and has authored about 12 journal papers and 3 book review chapters. Dr. Sharma has developed a unique drug / technology selection model for various drug delivery platforms. Dr. Sharma has successfully transferred the complex drug delivery technology from Japan to USA. A local company has used this model in technology selection and saved about 900K dollars with the help of this model. (This is me - Update Profile)
Employment History
- 2003 - present
- President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
GLG NewsSM Analyses by Kuldeepak Sharma, PhD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Good and Bad From Astellas Joint Venture With Maxygen
July 5, 2009
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals | www.pipelinereview.com
I read this news with great interest. This joint venture called (MPC) will advance Maxy 4 development program for rheumatoid arthritis and transplant rejection. Maxygen & Astellas are committing $ 10 million each for this joint venture. Since I have worked with Astellas (Yamanouchi) and based...
-
Efalizumab Withdrawn Due to Serious Side Effect
April 16, 2009
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
Efalizumab withdrawn from US Market | www.medscape.com
I read with great interest that Genentech, the maker of Raptiva (Efalizumab) to treat psoriasis, has begun a voluntary, phased withdrawal of the drug from the U.S. market. The drug is not being withdrawn immediately to give physicians and patients taking Raptiva time to safely and appropriately discontinue...
-
Various Generic Topiramate Tablets Approved by FDA
March 31, 2009
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
Ranbaxy, Aurobindo get US FDA nod for epilepsy drug | economictimes.indiatimes.com
As a Pharmaceutical consultant and pharmacist I read this article with great interest since prices Topiramate will further reduced due to additional generic company. Topamax® is very useful drug for the treatment of adult and pediatric Epilepsy. On September 2006, Mylan Pharmaceuticals Inc. received...
-
No Bidding War For CV Therapeutics From Astellas
March 17, 2009
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma
Astellas to Terminate Offer for CV Therapeutics | www.pipelinereview.com
I read this news with great interest since I have worked with Astellas (Yamanouchi). Based on my experience with Astellas I am not surprise that Astellas did not increase prices (although Astellas had so much to gain from a merger with CV) due the these reasons: * Astellas (as a Japanese company) is...
Leading institutions connect with Kuldeepak Sharma, PhD through GLG
GLG Study Groups with Kuldeepak Sharma, PhD(?)
| Study Group Name | No. Members |
|---|---|
| Physicians who Treat Onychomycosis (US) | 121 |
| Opana ER Prescribers (US) | 105 |
| Prescribers of Aldara (US) | 84 |
| Medical Tourism Experts | 358 |
GLG Live Meetings with Kuldeepak Sharma, PhD(?)
Recent Seminars
-
July 31, 2007 | San Francisco
GLGi: Drug Delivery Technologies